Treatments | | | | |
Median treatment procedures (25%, 75%) | | 5 (3, 9) | 3 (2, 4) | .0068a |
Range treatment procedures | | 2–19 | 2–7 | |
Any surgical treatment | | 63% | 33% | .17b |
Transarterial embolization | | 100% | 80% | .076b |
Transvenous embolization | | 74% | 67% | .72b |
Ethanol embolization | | 84% | 67% | .42b |
Coil embolization | | 89% | 80% | .63b |
PVA embolization | | 74% | 53% | .29b |
Glue embolization | | 42% | 13% | .13b |
Onyx embolizationc | | 11% | 20% | .63b |
Outcomes at last follow-up | | | | |
Mean follow-up duration | 4.6 y | 5.1 y | 4.0 y | .70 |
Median (range) follow-up duration | 2.5 y (56 d to 23 y) | 3.9 y (58 d to 17 y) | 1.4 y (56 d to 23 y) | .37a |
Death | | 16% | 0% | .24b |
Median outcome (normal = 0, deficits/residual fistula = 1, death = 2) | | 1 (0, 1) | 1 (0, 1) | .31a |
Median last mRS (25%, 75%) | | 1 (0, 3) | 1 (0, 3) | .39a |
Range last mRS | | 0–6 | 0–3 | |
Good outcome (last mRS 0–2) | | 74% | 73% | 1.0 |
Median change in mRS (25%, 75%) | | −0.5 (−1, 0) | −1 (−1, 0) | .83a |
Range change mRS | | −3 to 1 | −4 to 2 | |